On Tuesday, Pfizer expressed optimism over the prospect of providing a coronavirus vaccine in 2020.
Pfizer Chief Executive Albert Bourla said the drug giant could supply some 40 million doses in the United States in 2020 if clinical testing proceeds as expected and regulators approve a vaccine.
He said: “If all goes well, we will be ready to distribute an initial number of doses,” who pointed to a US government contract for Pfizer to supply 40 million doses by the end of this year and 100 million doses by March 2021.
But Bourla said the company still had not reached key benchmarks in assessing vaccine efficacy.
Bourla said the company expects to file for emergency use authorization for its Covid-19 vaccine in the third week of November, roughly in line with earlier timetables.
